Importantly, in a model of Alzheimer’s disease with both Aβ and tau pathology, decreasing tau oligomers was not only effective at altering cognitive and synaptic dysfunction, but also shifted toxic oligomeric Aβ to a non-toxic conformation [54]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.